Peptide Bio IndexEvidence first. Hype last.
⌕

Retatrutide Research Timeline: Phase 1 Through Phase 3 and Current Development Status

Written by

in

Peptide Research Overviews
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited9 min readUpdated Sep 10, 2026
Jump to a section
  1. Mechanism and molecule overview
  2. Phase 1 and early human evidence
  3. Phase 2 randomized clinical evidence — obesity, type 2 diabetes, and MASLD
  4. Phase 3 TRIUMPH registrational program and design
  5. Development status, ongoing trials, and regulatory context
  6. Safety, tolerability, and body-composition considerations observed in trials
  7. Reported study-design details from cited sources
  8. Limitations and research gaps
  9. Documentation checklist
  10. Related research supplies
  11. More Retatrutide research
  12. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

This deep dive summarizes the clinical development timeline and current development program for retatrutide (LY3437943), a triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors, using peer-reviewed phase 2 clinical data and publications describing the phase 3 TRIUMPH program and related phase 2 studies. Key randomized phase 2 trials reported substantial, dose-dependent weight loss and glycaemic improvements and provide the basis for the phase 3 registrational program described in TRIUMPH publications and trial design documents (sources: S1, S6, S7, S4).

Mechanism and molecule overview

Retatrutide (LY3437943) is described in the peer-reviewed literature as a single synthetic peptide that acts as an agonist at three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors (S1, S6, S7). [S1] [S6] [S7]

Phase 1 and early human evidence

Authors of a phase 2 diabetes trial note that earlier phase 1 data showed clinically meaningful glucose-lowering and weight-lowering activity of retatrutide, but specific phase 1 protocol details and dosing regimens are not reported in the reviewed source (S6). [S6]

Phase 2 randomized clinical evidence — obesity, type 2 diabetes, and MASLD

A phase 2, double-blind, randomized, placebo-controlled obesity trial (n=338) administered once-weekly subcutaneous retatrutide across multiple randomized dose arms (1 mg, combined 4 mg, combined 8 mg, and 12 mg with specific starting-dose escalation strategies) versus placebo for 48 weeks; the primary endpoint reported was percent change in body weight at 24 weeks, with efficacy reported through 48 weeks (S1). [S1]

A separate phase 2 randomized, placebo- and active-controlled trial in adults with type 2 diabetes (n=281 randomized; 275 in efficacy analyses) tested multiple retatrutide doses (0.5 mg, 4 mg with or without escalation, 8 mg with slow or fast escalation, 12 mg escalation) versus placebo and dulaglutide; the primary endpoint was change in HbA1c at 24 weeks with secondary assessments at 36 weeks, and bodyweight reductions were reported through 36 weeks (S6). [S6]

A randomized phase 2a trial in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) enrolled 98 participants from the obesity phase 2 study and randomized them to once-weekly subcutaneous retatrutide (1, 4, 8, or 12 mg) or placebo for 48 weeks; liver fat reductions at 24 weeks were reported as the substudy primary objective (S7). [S7]

Across these phase 2 publications, retatrutide treatment produced dose-dependent effects on body weight, glycaemic measures, and liver fat in the reported trial populations; adverse-event profiles were dominated by dose-related gastrointestinal events, and dose-dependent increases in heart rate were observed in at least one obesity study with a peak at 24 weeks (S1, S6, S7). [S1] [S6] [S7]

Phase 3 TRIUMPH registrational program and design

The TRIUMPH program is described as a coordinated registrational clinical development program consisting of four Phase 3, multicenter, randomized, double-blind trials that will evaluate once-weekly subcutaneous retatrutide versus placebo alongside diet and physical activity in over 5,800 participants, using a basket design to assess weight management plus obstructive sleep apnoea (OSA) and knee osteoarthritis (OA) endpoints (primary endpoints vary by substudy) (S4). [S4]

TRIUMPH-1 and TRIUMPH-2 are weight-management basket trials with nested OSA and/or OA protocols; TRIUMPH-3 assesses weight management in a population with cardiovascular disease, and TRIUMPH-4 is a stand-alone OA trial. The program permits independent analyses of weight management, OSA, and OA outcomes with a controlled type I error strategy (S4). [S4] [S8]

Development status, ongoing trials, and regulatory context

Review articles and systematic reviews describe retatrutide as an investigational GLP-1/GIP/glucagon triple agonist with ongoing phase 3 development (the TRIUMPH program) and identify retatrutide among a set of incretin-based agents progressing through late-stage trials; specific regulatory approvals or marketing authorizations are not reported in the reviewed sources (S2, S8, S4). [S2] [S8] [S4]

Safety, tolerability, and body-composition considerations observed in trials

Phase 2 reports note dose-related gastrointestinal adverse events (nausea, diarrhoea, vomiting, constipation) across retatrutide dose groups and that gastrointestinal events were mostly mild to moderate; a lower starting dose partially mitigated gastrointestinal events in one study, and dose-dependent increases in heart rate were reported to peak at 24 weeks in an obesity trial (S1, S6). [S1] [S6]

Narrative review literature highlights that incretin-based weight-loss agents, including triple-agonist molecules such as retatrutide, are associated with substantial mean weight loss alongside concerns about loss of lean mass, and recommends consideration of resistance exercise to preserve muscle mass in the context of incretin therapy — the review frames this as a broad clinical consideration rather than a trial-specific finding (S5). [S5]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S1] Phase 2 randomized, double-blind, placebo-controlled trial Adults with obesity (BMI ≥30 or BMI 27– 1 mg; 4 mg (with initial dose 2 mg or 4 mg); 8 mg (with initial dose 2 mg or 4 mg); 12 mg (initial dose 2 mg) Subcutaneous Once weekly 48 weeks (primary weight endpoint at 24 weeks; results reported through 48 weeks) Randomized allocation included multiple retatrutide dose arms (1 mg; combined 4 mg with two starting-dose strategies; combined 8 mg with two starting-dose strategies; 12 mg with starting-dose escalation) and placebo; primary endpoint was percent change in body weight at 24 weeks; safety assessments included GI events and heart rate.
[S6] Phase 2 randomized, double-blind, placebo- and active-controlled parallel-group trial Adults with type 2 diabetes (HbA1c 7.0–10.5%; BMI 25–50 kg/m2) 0.5 mg; 4 mg (starting dose 2 mg or no escalation); 8 mg (starting dose 2 mg or 4 mg); 12 mg (starting dose 2 mg) Subcutaneous Once weekly 24 weeks (primary HbA1c endpoint); secondary endpoints assessed at 36 weeks Comparator arms included placebo and 1.5 mg dulaglutide; multiple retatrutide maintenance-dose groups studied with various starting-dose escalation strategies; primary endpoint change in HbA1c at 24 weeks; bodyweight reported at 36 weeks.
[S7] Phase 2a randomized, double-blind, placebo-controlled trial (substudy) Participants with metabolic dysfunction-associated steatotic liver disease (MASLD) and ≥10% liver fat (substudy drawn from obesity trial population) 1 mg; 4 mg; 8 mg; 12 mg Subcutaneous Once weekly 48 weeks (primary substudy liver-fat endpoint assessed at 24 weeks) n=98 randomized to retatrutide (1, 4, 8, or 12 mg) or placebo; primary objective was mean relative change from baseline in liver fat at 24 weeks; liver-fat normalisation and correlations with weight and metabolic measures reported.
[S4] Phase 3 program (TRIUMPH) — four multicenter randomized, double-blind trials (basket design) Adults with overweight/obesity and nested populations with OSA and knee OA; population subsets include participants with CVD for one trial not reported in the reviewed source Subcutaneous Once weekly Not reported in the reviewed source TRIUMPH consists of TRIUMPH-1 and TRIUMPH-2 (weight-management basket trials with nested OSA and/or OA protocols), TRIUMPH-3 (weight management in population with cardiovascular disease), and TRIUMPH-4 (stand-alone OA trial); the program plans enrollment in over 5,800 participants and uses percent change in body weight as the primary weight-management endpoint, with AHI for OSA and WOMAC pain subscale for knee OA as other primary endpoints; details on individual trial duration are not reported in the reviewed source.

Limitations and research gaps

  • No reviewed source documents any regulatory approval, authorization, or marketing decision for retatrutide; regulatory status is not reported in the reviewed sources.
  • Phase 1 protocol-level details (specific dosing schedules, sample sizes, and endpoints) are not reported in the reviewed source excerpts.
  • Long-term safety outcomes, cardiovascular- and mortality-related endpoints, and durability of effect beyond the trial durations reported remain under investigation and are not fully addressed in the reviewed phase 2 publications.
  • Population diversity and subgroup analyses (including underrepresented racial/ethnic groups and broader comorbidity spectra) are incompletely described in the provided excerpts.
  • Cost, access, and real-world effectiveness data are not included in the reviewed sources.

Documentation checklist

  • Confirm current clinicaltrials.gov entries (TRIUMPH trials) for updates before publishing
  • Do not provide patient dosing, administration, or treatment advice — present trial details as study design only
  • Cross-check sponsor press releases and regulatory agency databases for any post-publication decisions
  • Flag any new peer-reviewed phase 3 readouts for incorporation in future updates
  • Verify population diversity and subgroup reporting in full trial manuscripts prior to clinical extrapolation
  • Clinical trial cold-chain storage logs template (for investigational product accountability)
  • Blinding and labelling documentation templates for randomized placebo-controlled trials
  • Good Clinical Practice (GCP) source-data and monitoring checklists
  • Electronic case report form (eCRF) setup and audit-trail documentation templates

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: SourcePoint Research currently lists SPR-3RT for research-use-only sourcing. Review current availability and the exact batch documentation at SourcePointResearch.com. This article does not independently certify a SourcePoint batch. Peptide Bio Index is affiliated with SourcePoint Research.

More Retatrutide research

Sources and references

  1. [S1] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.. The New England journal of medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972
  2. [S2] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy.. Biomolecules. 2025. PMID: 40563436. DOI: 10.3390/biom15060796
  3. [S3] Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.. Diabetes care. 2024. PMID: 38843460. DOI: 10.2337/dci24-0003
  4. [S4] Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.. Diabetes, obesity & metabolism. 2026. PMID: 41090431. DOI: 10.1111/dom.70209
  5. [S5] Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes care. 2024. PMID: 38687506. DOI: 10.2337/dci23-0100
  6. [S6] Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.. Lancet (London, England). 2023. PMID: 37385280. DOI: 10.1016/S0140-6736(23)01053-X
  7. [S7] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.. Nature medicine. 2024. PMID: 38858523. DOI: 10.1038/s41591-024-03018-2
  8. [S8] Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L. Emerging pharmacotherapies for obesity: A systematic review.. Pharmacological reviews. 2025. PMID: 39952695. DOI: 10.1124/pharmrev.123.001045

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts